Newron Pharmaceuticals S.p.A. | WebDisclosure

Switch to English

11200	Sociétés
247841	Mots-clés
175592	Articles
133916	Communiqués

Accueil
Sociétés
Newron Pharmaceuticals S.p.A.

COMMUNIQUÉ DE PRESSE

publié le 05/09/2025 à 07:00, il y a 1 année 1 mois

Newron to present data and updates on its clinical program evaluating evenamide as an add-on treatment for schizophrenia at the 2025 World Congress of Biological Psychiatry (WCBP)
Newron Pharmaceuticals to present data on evenamide as add-on treatment for schizophrenia at 2025 WCBP. Focus on efficacy, safety, and mechanism of action. Landmark studies showcased

Clinical Program Schizophrenia Newron Pharmaceuticals Evenamide WCBP
BRÈVE

publiée le 12/08/2025 à 07:05, il y a 1 année 2 mois

Newron Initiates Phase III ENIGMA-TRS Study for Treatment-Resistant Schizophrenia

Newron Pharmaceuticals Evenamide Schizophrenia Treatment Phase III Study TRS Therapy
BRÈVE

publiée le 12/08/2025 à 07:05, il y a 1 année 2 mois

Newron lance l'étude de phase III ENIGMA-TRS pour la schizophrénie résistante au traitement

Newron Pharmaceuticals Evenamide Traitement De La Schizophrénie Étude De Phase III Thérapie TRS
COMMUNIQUÉ DE PRESSE

publié le 12/08/2025 à 07:00, il y a 1 année 2 mois

Newron begins enrollment in pivotal Phase III ENIGMA-TRS program with evenamide as add-on therapy in patients with treatment-resistant schizophrenia (TRS)
Newron Pharmaceuticals initiates Phase III ENIGMA-TRS program with evenamide as add-on therapy for treatment-resistant schizophrenia patients, targeting TRS population

Newron Pharmaceuticals Evenamide Phase III Treatment-resistant Schizophrenia ENIGMA-TRS Program
BRÈVE

publiée le 11/08/2025 à 07:05, il y a 1 année 2 mois

Newron Pharmaceuticals' Evenamide Shows Promise in Schizophrenia Treatment

Newron Pharmaceuticals Schizophrenia Treatment Evenamide Research Glutamate Modulation Neuropsychopharmacology Study
BRÈVE

publiée le 11/08/2025 à 07:05, il y a 1 année 2 mois

L'Evenamide de Newron Pharmaceuticals s'avère prometteur dans le traitement de la schizophrénie

Newron Pharmaceuticals Traitement De La Schizophrénie Recherche Sur L'évenamide Modulation Du Glutamate Étude De Neuropsychopharmacologie
COMMUNIQUÉ DE PRESSE

publié le 11/08/2025 à 07:00, il y a 1 année 2 mois

Newron notes the publication of new preclinical research suggesting evenamide ameliorates schizophrenia-related dysfunction
Newron Pharmaceuticals notes new preclinical research indicating evenamide may improve schizophrenia-related dysfunction by targeting hippocampal pathology. Study shows potential for novel therapeutic strategy

Schizophrenia Newron Pharmaceuticals Evenamide Preclinical Research Hippocampus
BRÈVE

publiée le 12/05/2025 à 07:05, il y a 1 année 5 mois

Newron's ENIGMA-TRS Phase III Program Approved for Treatment-Resistant Schizophrenia

Newron Pharmaceuticals Evenamide Phase III ENIGMA-TRS Treatment-resistant Schizophrenia Glutamatergic Modulation
BRÈVE

publiée le 12/05/2025 à 07:05, il y a 1 année 5 mois

Le programme ENIGMA-TRS de phase III de Newron approuvé pour le traitement de la schizophrénie résistante au traitement

Newron Pharmaceuticals Evenamide Phase III ENIGMA-TRS Schizophrénie Résistante Au Traitement Modulation Glutamatergique
COMMUNIQUÉ DE PRESSE

publié le 12/05/2025 à 07:00, il y a 1 année 5 mois

Newron announces approval for pivotal Phase III ENIGMA-TRS program with evenamide as add-on therapy in patients with treatment-resistant schizophrenia (TRS)
Newron Pharmaceuticals announces approval for pivotal Phase III ENIGMA-TRS program evaluating evenamide as add-on therapy in treatment-resistant schizophrenia patients. Study results expected in Q4 2026

Newron Pharmaceuticals Evenamide Phase III Treatment-resistant Schizophrenia ENIGMA-TRS Program

Les Echos

Publié le 19/10/2026 à 11:45, il y a 4 heures 19 minutes

Guillemot Corporation S.A. | Déclaration hebdomadaire des transactions sur actions propres du 12 au 16 octobre 2026
Publié le 19/10/2026 à 11:45, il y a 4 heures 19 minutes

Guillemot Corporation S.A. | Weekly report share buyback from October 12 to October 16, 2026
Publié le 19/10/2026 à 10:49, il y a 5 heures 15 minutes

261019 BENETEAU Transactions sur actions propres
Publié le 19/10/2026 à 08:15, il y a 7 heures 50 minutes

Carrefour strengthens its leadership in convenience retail in France with the acquisition of Codifrance
Publié le 19/10/2026 à 08:15, il y a 7 heures 50 minutes

Carrefour renforce son leadership dans le commerce de proximité en France avec l’acquisition de Codifrance

Voir tout LES ECHOS COMFI WIRE

Accesswire

Publié le 19/10/2026 à 14:30, il y a 1 heure 35 minutes

Core Silver Intersects Copper Bearing VMS Mineralization at the Touleary Project
Publié le 19/10/2026 à 14:00, il y a 2 heures 5 minutes

Four Nines Gold Intersects 80.1 Meters Averaging 1.08 g/t Gold in Expanding Lower Telegraph Corridor at Hayden Hill
Publié le 19/10/2026 à 13:30, il y a 2 heures 35 minutes

Empress Announces Closing of Tongon Gold Stream Investment and Debt Financing
Publié le 19/10/2026 à 13:30, il y a 2 heures 35 minutes

Mako Mining Announces Q3 2026 Production Results with Gold Recovered of 12,743 oz Au (Sales of 11,581 oz Au), and Positive Permitting Updates at Mt. Hamilton and San Albino
Publié le 19/10/2026 à 13:01, il y a 3 heures 4 minutes

CoTec Holdings Corp. Notes HyProMag USA Deployment of Mobile Inserma System, Extending Hard Disk Drive Processing to Customer Sites Across the United States

Voir tout ACCESSWIRE

EQS Group

Publié le 19/10/2026 à 15:55, il y a 10 minutes

"Feel your glo™": Artwork becomes fashion - Marcel Ostertag presents his exclusive fashion piece at the grand campaign finale in Hamburg
Publié le 19/10/2026 à 15:50, il y a 15 minutes

Financial Street Forum's annual conference opens
Publié le 19/10/2026 à 15:45, il y a 20 minutes

New Private Equity partners with ONE group solutions to build the data-driven fund governance platform for global asset managers
Publié le 19/10/2026 à 15:32, il y a 32 minutes

Cairn Homes Plc: Holding(s) in Company
Publié le 19/10/2026 à 15:15, il y a 50 minutes

Quantinuum Breaks Error-Correction World Record by 10x, Validating Its Leading Path to Fault-Tolerant Quantum Computing by 2029